Market Place
Sourcing Support
Anaptys Announces Participation At Upcoming Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
Anaptys To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
Anaptys Announces Participation In December Investor Conferences
25 Nov 2025 //
GLOBENEWSWIRE
GSK, Anaptysbio sue each other over Jemperli revenue
22 Nov 2025 //
BIOPHARMADIVE
Anaptysbio Abandons Rosnilimab For UC After Phase 2 Fail
10 Nov 2025 //
FIERCE BIOTECH
Anaptys Reveals Q3 2025 Financials & Business Update
04 Nov 2025 //
GLOBENEWSWIRE
Anaptys Announces Participation In November Investor Conferences
04 Nov 2025 //
GLOBENEWSWIRE
Anaptys Show Positive Ph 2b Trial Results for Rosnilimab in RA
29 Oct 2025 //
GLOBENEWSWIRE
Anaptys Reveals Full Phase 2B Rosnilimab Data In Ra At ACR
13 Oct 2025 //
GLOBENEWSWIRE
Anaptys Announces Participation in September Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Anaptys Reveals Q2 2025 Financials and Updates on Business
06 Aug 2025 //
GLOBENEWSWIRE
Anaptys reports positive Rosnilimab data in Phase 2b RA trial.
03 Jun 2025 //
GLOBENEWSWIRE
Anaptys to Update Data from Phase 2b Trial of Rosnilimab on June
27 May 2025 //
GLOBENEWSWIRE
Anaptys reports Q1 2025 results and business update
05 May 2025 //
GLOBENEWSWIRE
Anaptys Announces Stock Repurchase Plan
24 Mar 2025 //
GLOBENEWSWIRE
Anaptys’ Rosnilimab Shows Positive Results In RA Ph 2b Trial
12 Feb 2025 //
GLOBENEWSWIRE
Anaptys To Reveal Ph 2b Rosnilimab Data In RA On Feb 12
11 Feb 2025 //
GLOBENEWSWIRE
Vanda & Anaptys Announce Agreement for Imsidolimab Development
03 Feb 2025 //
PR NEWSWIRE
Anaptys to Present at Guggenheim SMID Cap Biotech Conference
03 Feb 2025 //
GLOBENEWSWIRE
Anaptys to Present at the 43rd Annual J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
AnaptysBio Ends Eczema Drug Development After Trial Failure
11 Dec 2024 //
REUTERS
Anaptys scraps atopic dermatitis asset after ph. 2 fail
10 Dec 2024 //
FIERCE BIOTECH
Anaptys Announces Participation in Nov & Dec Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Anaptys Announces Q3 2024 Financial Results & Business Update
05 Nov 2024 //
GLOBENEWSWIRE
Anaptys Announces Participation in September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Anaptys Announces Pricing Of $100 Million Direct Offering
14 Aug 2024 //
GLOBENEWSWIRE
Anaptys Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
Anaptys Positive Imsidolimab Phase 3 Results In Pustular Psoriasis
09 May 2024 //
GLOBENEWSWIRE
Anaptys to Present Phase 1 Data on ANB032
11 Oct 2023 //
GLOBENEWSWIRE
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab
02 May 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Portfolio Update Across Immune Cell Modulating Antibodies
05 Jan 2023 //
PRESS RELEASE
